Discovery of a Selective S1P(1) Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate

[Image: see text] Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors (S1P(1) and S1P(3−5)). It has be...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Demont, Emmanuel H., Andrews, Benjamin I., Bit, Rino A., Campbell, Colin A., Cooke, Jason W. B., Deeks, Nigel, Desai, Sapna, Dowell, Simon J., Gaskin, Pam, Gray, James R. J., Haynes, Andrea, Holmes, Duncan S., Kumar, Umesh, Morse, Mary A., Osborne, Greg J., Panchal, Terry, Patel, Bela, Perboni, Alcide, Taylor, Simon, Watson, Robert, Witherington, Jason, Willis, Robert
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Chemical Society 2011
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4018134/
https://ncbi.nlm.nih.gov/pubmed/24900328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml2000214
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन